Posted on September 18, 2025December 8, 2025 by snkadmin Inspection Backlogs Post-COVID 2025 In the wake of COVID-19, global regulators are still working through substantial backlogs in pharmaceutical manufacturing site inspections. For the industry, these delays add uncertainty to supply chain planning, maintaining compliance, and anticipating regulatory measures. Using the QYOBO platform, we analysed more than 32,000 inspections and over 5,000 pharmaceutical manufacturing sites worldwide, revealing notable changes in the scale and frequency of regulatory oversight since 2020. Download the Whitepaper Fill out the form to get your free download link by email.
Posted on July 31, 2025December 8, 2025 by Lena Herrmann GLP-1 Market Overview 2025 Amid rapid market growth, this report examines the evolving GLP-1 supply landscape, drawing on QYOBO’s visibility into global manufacturing, regulatory activity, and pricing trends. It outlines the shift from Europe-based production toward Asia and covers revenue distribution, infrastructure investments, API pricing, and site-level compliance to support strategic decision-making across the pharmaceutical industry. Download the whitepaper Fill out the form to get your free download link by email.
Posted on July 11, 2025December 8, 2025 by Lena Herrmann API Market: Trends in Drug Master Filings Across the U.S., Europe, Japan and China in 2025 QYOBO’s intelligence platform is the world’s first to map the entire pharmaceutical manufacturing universe at site level. Drawing on QYOBO’s visibility into over 15,000 manufacturing sites worldwide, combined with Drug Master Filings (DMF) data from EDQM, NMPA, PMDA, and USFDA, this is the first analysis to compare API submissions across the U.S., Europe, Japan, and China. DOWNLOAD THE WHITEPAPER Fill out the form to get your free download link by email.
Posted on April 9, 2025December 8, 2025 by Lena Herrmann Big-Data-Driven M&A in Pharma: The Competitive Edge of Site-level Intelligence Private equity investments are transforming the pharmaceutical manufacturing sector, unlocking new opportunities amid shifting global market dynamics. With over 1,400 manufacturing sites across Europe, strategic acquisitions require data-driven insights to navigate compliance risks, ownership complexities, and supply chain dependencies. Discover how advanced analytics platforms empower investors to make informed M&A decisions and gain a competitive edge in this evolving landscape. DOWNLOAD THE WHITEPAPER Fill out the form to get your free download link by email.
Posted on February 14, 2025December 8, 2025 by Lena Herrmann API Market: 5-Year Trends in USDMF and CEP Approvals The API market is evolving rapidly, with regulatory approvals on the rise and manufacturing shifting towards Asia. Over the past five years, USDMF and CEP approvals have grown significantly, reflecting increasing demand for APIs in key therapeutic areas. India and China have emerged as dominant players, reshaping the industry landscape. What do these trends mean for the future of pharmaceutical manufacturing? Explore our latest insights. DOWNLOAD THE WHITEPAPER Fill out the form to get your free download link by email.
Posted on February 2, 2025December 8, 2025 by Lena Herrmann FDA Drug Approvals: Key Trends, Leading Companies and Innovation Hubs FDA drug approvals serve as the pulse of pharmaceutical innovation. Between 2015 and 2024, the FDA approved 462 new drugs – a 69% increase from the previous decade. However, annual growth has slowed, indicating that investments in drug development are outpacing new approvals. DOWNLOAD THE WHITEPAPER Fill out the form to get your free download link by email.
